Aclaris Therapeutics (ACRS) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 37.1% versus a gain of 1.9%. Over five years, ZVRA leads with a +8.8% price change compared with -72.7% for ACRS. Aclaris Therapeutics is the larger company by market cap ($545.6 million vs $521.3 million), about 1.0 times the size, while Zevra Therapeutics is growing revenue faster (+350.9% vs -58.2%).
Zevra Therapeutics converts more of its revenue into profit, with a net margin of 78.2% versus -829.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | ZVRA |
|---|---|---|
| Share price | $3.44 | $8.76 |
| Market cap | $545.63M | $521.26M |
| 1-day change | -1.71% | -3.42% |
| YTD return | +14.29% | -2.23% |
| 1-year return | +37.05% | +1.86% |
| 5-year return | -72.74% | +8.82% |
| P/E ratio (TTM) | — | 7.18 |
| Forward P/E | — | 9.84 |
| EPS (TTM) | $-0.59 | $1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.83M | $106.47M |
| Revenue growth (YoY) | -58.19% | +350.91% |
| Net income (latest FY) | $-64.92M | $83.23M |
| Gross margin | 73.28% | 84.52% |
| Operating margin | -975.91% | -59.12% |
| Net margin | -829.58% | 78.17% |
| 52-week high | $6.60 | $15.04 |
| 52-week low | $2.46 | $8.01 |
| Distance from 52-week high | -47.88% | -41.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +205.23% | +162.56% |
| Average volume | 3.07M | 954.53K |
| Shares outstanding | 158.61M | 59.50M |
| Employees | 69 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed ZVRA by 35.2 percentage points over the past year.
- Zevra Therapeutics is more profitable, keeping 78.2 cents of every revenue dollar as net income versus -829.6 cents for Aclaris Therapeutics.
- Zevra Therapeutics grew revenue faster in its latest fiscal year (+350.91% vs -58.19%).
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
ACRS vs ZVRA FAQ
Which is bigger, Aclaris Therapeutics or Zevra Therapeutics?
Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $545.63M compared with $521.26M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, ACRS or ZVRA?
ACRS returned +37.05% over the past 12 months, compared with +1.86% for ZVRA (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.